NCT04552288: Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a cancer therapy-related cutaneous (skin) adverse event (e.g. rash, itching, eczema) & must be willing to continue on culprit drugs

Comments are closed.

Up ↑